SCHEMBL5898644

SCHEMBL5898644

NC(=O)NNS(=O)(=O)c1cccs1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
TSHR P16473 1/20 0.51
SLC1A3 P43003 1/20 0.50
SLC1A2 P43004 1/20 0.50
SLC1A1 P43005 1/20 0.50
F2 P00734 2/20 0.49
PRSS1 P07477 2/20 0.49
PRSS2 P07478 2/20 0.49
PRSS3 P35030 2/20 0.49
GAA P10253 1/20 0.47
MEN1 O00255 6/20 0.46
KMT2A Q03164 6/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ALDH1A1 P00352 2/20 0.44
BRAF P15056 1/20 0.43
HKDC1 Q2TB90 1/20 0.43
MAPT P10636 3/20 0.43
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1760879 0.85 CYP2D6 (0.58) CYP2D6CYP2C9CYP2C19TSHRSLC1A3
SCHEMBL731549 0.82 CYP2D6 (0.55) CYP2D6CYP2C9CYP2C19TSHRSLC1A3
SCHEMBL24254325 0.81 CYP2D6 (0.67) CYP2D6CYP2C9CYP2C19TSHRGAA
Urea SCHEMBL8693555 0.81 CYP2D6 (0.53) CYP2D6CYP2C9CYP2C19TSHRSLC1A3
SCHEMBL28689240 0.79 KAT6A (0.61) CYP2D6CYP2C9CYP2C19TSHRSLC1A3
SCHEMBL8337692 0.75 CYP2C9 (0.64) CYP2D6CYP2C9CYP2C19TSHRGAA
SCHEMBL6934209 0.74 ALDH1A1 (0.57) CYP2D6CYP2C9CYP2C19TSHRSLC1A3
SCHEMBL10718657 0.74 CYP2D6 (0.53) CYP2D6CYP2C9CYP2C19TSHRSLC1A3
SCHEMBL8232303 0.74 CYP2D6 (0.62) CYP2D6CYP2C9CYP2C19TSHRSLC1A3
SCHEMBL1863910 0.74 CYP2D6 (0.62) CYP2D6CYP2C9CYP2C19TSHRSLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104822373-A Therapeutic compounds and compositions AGIOS PHARMACEUTICALS INC 2015-08-05 CN disclosed
US-20060030596-A1 NF-kappaB inhibitors SMITHKLINE BEECHAM CORPORATION 2006-02-09 US disclosed
EP-1324759-A4 NF-G(K)B INHIBITORS SMITHKLINE BEECHAM CORP (US) 2004-05-12 EP disclosed
US-20040024047-A1 Nf-kb inhibitors SMITHKLINE BEECHMAN CORPORATION 2004-02-05 US disclosed
EP-1324759-A2 NF-G(K)B INHIBITORS SmithKline Beecham Corporation (US) 2003-07-09 EP disclosed
WO-2002030353-A2 NF-λB INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030596-A1 NF-kappaB inhibitors NFKBIA, IKBKB, IKBKG CYP2D6 4539/4885CYP2C9 4706/4885CYP2C19 4750/4885
US-20040024047-A1 Nf-kb inhibitors NFKBIA, IKBKB, IKBKG CYP2D6 4308/4885CYP2C9 4440/4885CYP2C19 4479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.